menu

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Drug Info Rounds

FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval

close
FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
Restart
Resume
Read full article
Choose a format
Media formats available:
Details
Comments
  • Overview

    The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

    Released May 30, 2017.

Facebook Comments

Recommended
Details
Comments
  • Overview

    The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

    Released May 30, 2017.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/29/20